
Graft versus host disease (GvHD) - Pipeline Insight, 2024
Description
Graft versus host disease (GvHD) - Pipeline Insight, 2024
DelveInsight’s, “Graft versus host disease (GvHD) - Pipeline Insight, 2024” report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Graft versus host disease (GVHD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Graft versus host disease (GVHD): Overview
Graft versus host disease (GVHD) is a serious complication that occurs when donor immune cells attack the recipient’s body following an allogeneic stem cell or bone marrow transplant. This condition arises because the donor's immune cells, recognizing the recipient's cells as foreign, initiate an immune response against them. GVHD primarily involves T-cells from the donor graft and can be classified into two main types: acute and chronic. Acute GVHD typically develops within the first 100 days post-transplant, manifesting through symptoms like skin rashes, jaundice, liver enzyme abnormalities, and diarrhea. Chronic GVHD, on the other hand, occurs after 100 days and can affect multiple organs, leading to symptoms such as skin thickening, joint contractures, dry eyes, and lung dysfunction.
The risk of developing GVHD is influenced by several factors, including the degree of HLA matching between donor and recipient, the type of donor, and the recipient’s age. Mismatched HLA significantly increases the risk, as does the use of unrelated or haploidentical donors and cord blood transplants compared to matched sibling donors. Older recipients are also more prone to GVHD, and the intensity of the conditioning regimen (pre-transplant chemotherapy or radiation) plays a critical role in the disease's development. Diagnosis is based on clinical presentation, biopsy of affected tissues, and the exclusion of other potential causes of symptoms.
Preventive measures are crucial in managing GVHD, with prophylactic immunosuppressive therapies such as cyclosporine, tacrolimus, methotrexate, and mycophenolate mofetil commonly used. Treatment of acute GVHD generally involves high-dose corticosteroids, with additional immunosuppressive agents like ruxolitinib and antithymocyte globulin (ATG) used for steroid-refractory cases. Chronic GVHD treatment also includes corticosteroids and calcineurin inhibitors, with newer therapies such as ibrutinib and ruxolitinib for refractory cases. Despite these treatments, GVHD can lead to significant morbidity and mortality due to direct organ damage and increased infection risk from prolonged immunosuppression.
The prognosis for GVHD varies widely; acute GVHD presents an immediate risk of severe outcomes, while chronic GVHD can cause long-term health issues. Effective prevention and treatment strategies are essential to improving patient outcomes and quality of life. Complications of GVHD include chronic infections, secondary cancers, and debilitating organ dysfunction, underscoring the importance of ongoing management and monitoring.
Research is continuously advancing to better understand the mechanisms underlying GVHD and to develop more targeted therapies. Innovations in immunotherapy and personalized medicine approaches hold promise for reducing the incidence and severity of GVHD. These advancements are crucial for enhancing the success rates of transplants and improving the overall prognosis for patients affected by this challenging condition.
""Graft versus host disease (GVHD)- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Graft versus host disease (GVHD) pipeline landscape is provided which includes the disease overview and Graft versus host disease (GVHD) treatment guidelines. The assessment part of the report embraces, in depth Graft versus host disease (GVHD) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Graft versus host disease (GVHD) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Graft versus host disease (GVHD) R&D. The therapies under development are focused on novel approaches to treat/improve Graft versus host disease (GVHD).
This segment of the Graft versus host disease (GVHD) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Graft versus host disease (GVHD) Emerging Drugs
- Itolizumab: Equillium
- ABSK021: Abbisko Therapeutics
- SYN-004: Theriva Biologics
- SER-155: Seres Therapeutics
Further product details are provided in the report……..
Graft versus host disease (GVHD): Therapeutic Assessment
This segment of the report provides insights about the different Graft versus host disease (GVHD) drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Graft versus host disease (GVHD)
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intravenous
- Subcutaneous
- Oral
- Intramuscular
- Molecule Type
- Monoclonal antibody
- Small molecule
- Peptide
- Product Type
Graft versus host disease (GVHD): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Graft versus host disease (GVHD) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Graft versus host disease (GVHD) drugs.
Graft versus host disease (GVHD) Report Insights
- Graft versus host disease (GVHD) Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Graft versus host disease (GVHD) drugs?
- How many Graft versus host disease (GVHD) drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Graft versus host disease (GVHD)?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Graft versus host disease (GVHD) therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Graft versus host disease (GVHD) and their status?
- What are the key designations that have been granted to the emerging drugs?
- Abbisko Therapeutics
- Equillium
- Theriva Biologics
- Seres Therapeutics
- CytoMed Therapeutics
- Beijing Tide Pharmaceutical Co., Ltd
- CTI BioPharma
- ViGenCell Inc.
- Lipella Pharmaceuticals
- Cellestia Biotech
- Seres Therapeutics
- Jiangsu HengRui Medicine Therapeutics
- Genentech
- AltruBio
- Orca Bio
- GSK
- Amgen
- ABSK021
- Itolizumab
- SYN-004
- SER-155
- Umbilical cord derived mesenchymal stem cell
- TDI01
- Pacritinib
- VM-001
- LP-410
- CB-103
- SER-155
- SHR0302
- RG-6287
- ALTB-168
- Orca-Q
- Belimumab
- Efavaleukin alfa
Table of Contents
180 Pages
- Introduction
- Executive Summary
- Graft versus host disease (GVHD): Overview
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Graft versus host disease (GVHD)– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Itolizumab: Equillium
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- ABSK021: Abbisko Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- SER-155: Seres Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Product Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Graft versus host disease (GVHD) Key Companies
- Graft versus host disease (GVHD) Key Products
- Graft versus host disease (GVHD)- Unmet Needs
- Graft versus host disease (GVHD)- Market Drivers and Barriers
- Graft versus host disease (GVHD)- Future Perspectives and Conclusion
- Graft versus host disease (GVHD) Analyst Views
- Graft versus host disease (GVHD) Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.